Subgroup Placebo n/N (K-M%) Serelaxin n/N (K-M%) Favours serelaxin Favours placebo Hazard ratio Estimate (95%CI) Interaction P value Total population 65/580.

Slides:

Advertisements

Similar presentations

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???

Advertisements

Hispanic population in Virginia STD Trends Data through 2006.

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo.

00003-E-1 – December 2004 Global summary of the HIV and AIDS epidemic, December 2004 The ranges around the estimates in this table define the boundaries.

analysis from the SHIFT study

Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and

The Demographic Transition Model (DTM) Mr Elliott SSOT.

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

OPTIMAL BLOOD PRESSURE LEVELS IN ELDERLY PERSONS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) COHORT STUDY Maciej Banach*,

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

אי ספיקת לב ופרפור פרוזדורים - מגדר ד"ר א. שוטן מכון הלב הילל יפה, חדרה.

Coverage with Evidence Development Implantable Cardioverter Defibrillators 1 Sean Tunis MD, MSc June 23, 2009.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Subgroup Placebo n/N (%) Serelaxin n/N (%)Favours placeboFavours serelaxin Odds ratio Estimate (95%CI) Interaction P value Total population150/580 (25.9)156/581.

MERLIN TIMI 36 M ETABOLIC E FFICIENCY WITH R ANOLAZINE FOR L ESS I SCHEMIA IN N STE ACS.

AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

CIBIS II Cardiac Insufficiency Bisoprolol Study

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

Supplemental Figure 2A. Time-varying all-cause mortality hazard ratios (and 95% confidence interval error bars) across pre-specified subgroups of Age (

Mihai Gheorghiade MD Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, Illinois On behalf of: Stephen.

Supplemental Table A. Baseline proteinuria predicting renal outcome in multivariable Cox-Hazard model PredictorsHR95% CIp value Baseline UPE, g/day

Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.

World Regions Geography Review Game

Enrollment Update 1 September 2015 Department of Mental Health and Substance Abuse Global Clinical Practice Network for Field Studies of ICD-11 Mental.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

Tailoring Intervention – Effectively Targeting the High-risk Population Cardiovascular Event Reduction in the Higher-Risk Primary Prevention Population.

Interim Chair, Medicine Brigham and Women’s Hospital Boston, MA

1 World Regions. 1 Southeast Asia 2 World Regions.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.

Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.

Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.

Regional Differences in Heart Failure Medication Changes During Acute Heart Failure Hospitalization: Findings From the PROTECT Trial Robert J. Mentz, Gad.

Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: Outcomes Associated With Microalbuminuria: Effect.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.

PJ Devereaux, MD, PhD McMaster University

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

1.08 (0.77, 1.51) 0.93 (0.74, 1.16) 0.84 (0.63, 1.12) 1.29 (0.24, 6.91) 1.10 (0.80, 1.52) 0.93 (0.74, 1.17) 1.50 (0.27, 8.34) 1.12 (0.39, 3.23) 0.81 (0.60,

Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.

REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.

New Insights from EXSCEL

Cardiovascular outcomes

תמותת תינוקות.

Patterns of Use of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Among Patients With Acute Myocardial Infarction in China From.

Effects of Intensive Blood Pressure Control on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes.

Estimated adult and child deaths from AIDS  2009

Western & Central Europe

U-shaped effect of eGFR and mortality

Volume 83, Issue 4, Pages (April 2013)

Regional HIV and AIDS statistics 2008 and 2001

Children (<15 years) estimated to be living with HIV as of end 2005

Regional HIV and AIDS statistics and features for women, 2004 and 2006

Regional HIV and AIDS statistics and features, end of 2004

Associations between type of MI and incident HF

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Presentation transcript:

Subgroup Placebo n/N (K-M%) Serelaxin n/N (K-M%) Favours serelaxin Favours placebo Hazard ratio Estimate (95%CI) Interaction P value Total population 65/580 (11.3)42/581 (7.3)0.63 (0.43, 0.93) Gender Male40/357 (11.3)28/368 (7.7) 0.67 (0.41, 1.08) Female25/223 (11.3)14/213 (6.7) 0.58 (0.30, 1.11) Age <65 years9/119 (7.6)11/145 (7.8) 1.01 (0.42, 2.43) ≥65 years56/461 (12.3)31/436 (7.2) 0.57 (0.37, 0.89) <75 years23/296 (7.8)24/315 (7.8) 0.98 (0.56, 1.74) ≥75 years42/284 (15.0)18/266 (6.8) 0.44 (0.25, 0.76) Region Eastern Europe35/282 (12.5)23/280 (8.3) 0.65 (0.38, 1.10) Western Europe9/101 (9.1)4/103 (4.2) 0.42 (0.13, 1.36) South America4/37 (10.9)4/34 (11.8) 1.09 (0.27, 4.37) North America5/55 (9.1)6/59 (10.2) 1.09 (0.33, 3.59) Israel12/105 (11.4)5/105 (4.8) 0.42 (0.15, 1.18) Race White / Caucasian62/552 (11.3)38/544 (7.1) 0.61 (0.41, 0.92) Other3/28 (10.7)4/37 (11.5) 0.94 (0.21, 4.21) Hosp. for CHF in past year Yes18/181 (9.9)23/216 (10.9) 1.10 (0.59, 2.04) No47/399 (11.9)19/365 (5.3) 0.42 (0.25, 0.72) SBP <140 mmHg38/284 (13.5)26/298 (8.9) 0.64 (0.39, 1.05) ≥140 mmHg27/294 (9.2)15/279 (5.5) 0.58 (0.31, 1.09) Heart rate <80 bpm32/296 (10.8)19/314 (6.1) 0.55 (0.31, 0.97) ≥80 bpm33/284 (11.8)23/267 (8.8) 0.73 (0.43, 1.24) LVEF <40%30/295 (10.2)24/303 (8.0) 0.77 (0.45, 1.32) ≥40%30/244 (12.4)16/249 (6.5) 0.51 (0.28, 0.94) History of IHD Yes38/307 (12.5)21/296 (7.1) 0.56 (0.33, 0.95) No27/273 (10.0)21/285 (7.5) 0.74 (0.42, 1.31) History of ICD or CRT Yes18/141 (12.9)17/153 (11.3) 0.87 (0.45, 1.69) No47/439 (10.8)25/428 (5.9) 0.53 (0.33, 0.87) History of DM Yes32/272 (11.8)21/279 (7.6) 0.63 (0.36, 1.10) No33/308 (10.8)21/302 (7.1) 0.64 (0.37, 1.10) History of AF Yes41/305 (13.6)23/297 (7.8) 0.56 (0.34, 0.94) No24/275 (8.8)19/284 (6.8) 0.76 (0.42, 1.39) AF at screening Yes36/246 (14.8)15/233 (6.5) 0.42 (0.23, 0.76) No29/333 (8.8)27/347 (7.9) 0.90 (0.53, 1.52) Time from present. to rand. <6 h27/266 (10.2)25/275 (9.2) 0.90 (0.52, 1.55) ≥6 h38/314 (12.2)17/306 (5.6) 0.44 (0.25, 0.79) ACEI/ARB use at baseline Yes38/398 (9.6)26/390 (6.8) 0.70 (0.42, 1.15) No27/182 (15.1)16/191 (8.5) 0.54 (0.29, 1.00) Beta-blocker use at baseline Yes43/407 (10.7)29/387 (7.6) 0.70 (0.44, 1.12) No22/173 (12.7)13/194 (6.8) 0.51 (0.26, 1.01) MRA use at baseline Yes20/173 (11.7)20/192 (10.6) 0.91 (0.49, 1.70) No45/407 (11.1)22/389 (5.7) 0.50 (0.30, 0.82) IV nitrates at baseline Yes7/42 (17.0)5/39 (12.8) 0.73 (0.23, 2.31) No58/538 (10.9)37/542 (6.9) 0.62 (0.41, 0.94) Lymphocytes at baseline ≤12%29/127 (23.2)9/110 (8.3) 0.32 (0.15, 0.69) >12%33/409 (8.1)30/425 (7.2) 0.88 (0.53, 1.44) Troponin T at baseline ≤0.024 μg/L 10/165 (6.1)6/176 (3.4) 0.56 (0.20, 1.54) –0.045 μg/L 14/196 (7.2)14/182 (7.7) 1.08 (0.52, 2.27) >0.045 μg/L 32/180 (18.0)17/175 (10.0) 0.51 (0.28, 0.92) NT-proBNP at baseline <5000 ng/L18/279 (6.5)16/288 (5.6) 0.86 (0.44, 1.69) ≥5000 ng/L41/272 (15.3)24/262 (9.3) 0.58 (0.35, 0.97) ≤3346 ng/L 9/190 (4.7)5/177 (2.8) 0.59 (0.20, 1.76) –7281 ng/L 20/174 (11.6)18/194 (9.4) 0.81 (0.43, 1.53) >7281 ng/L 30/187 (16.4)17/179 (9.6) 0.56 (0.31, 1.02) Cystatin C at baseline ≤1.26 mg/L 8/180 (4.5)11/189 (5.9) 1.33 (0.53, 3.30) –1.65 mg/L 22/191 (11.7)8/180 (4.5) 0.37 (0.17, 0.83) >1.65 mg/L 29/180 (16.2)21/181 (11.7) 0.70 (0.40, 1.23) eGFR at baseline <60 ml/min/1.73m 2 55/408 (13.6)30/409 (7.4) 0.53 (0.34, 0.83) ≥60 ml/min/1.73m 2 8/160 (5.0)10/155 (6.6) 1.30 (0.51, 3.29) <50 ml/min/1.73m 2 46/272 (17.1)21/268 (7.9) 0.44 (0.26, 0.74) ≥50 ml/min/1.73m 2 17/296 (5.8)19/296 (6.5) 1.13 (0.59, 2.17) Hazard ratio (95% CI) for all-cause mortality through Day 180